Cabaletta Bio, Inc. (NASDAQ:CABA) Shares Sold by Jane Street Group LLC

Jane Street Group LLC decreased its position in Cabaletta Bio, Inc. (NASDAQ:CABA) by 48.8% in the 3rd quarter, HoldingsChannel reports. The firm owned 157,702 shares of the company’s stock after selling 150,313 shares during the period. Jane Street Group LLC’s holdings in Cabaletta Bio were worth $744,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in CABA. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Cabaletta Bio in the third quarter valued at approximately $32,000. Point72 DIFC Ltd purchased a new stake in Cabaletta Bio in the 3rd quarter worth approximately $33,000. China Universal Asset Management Co. Ltd. raised its holdings in Cabaletta Bio by 65.7% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 9,395 shares of the company’s stock valued at $44,000 after acquiring an additional 3,724 shares during the last quarter. Intech Investment Management LLC purchased a new position in shares of Cabaletta Bio during the 3rd quarter worth $67,000. Finally, GSA Capital Partners LLP acquired a new stake in shares of Cabaletta Bio during the third quarter worth $127,000.

Analyst Ratings Changes

CABA has been the subject of several analyst reports. TD Cowen upgraded Cabaletta Bio to a “strong-buy” rating in a research note on Friday, November 29th. HC Wainwright reaffirmed a “buy” rating and set a $25.00 price objective on shares of Cabaletta Bio in a research note on Friday, November 15th. Wells Fargo & Company cut shares of Cabaletta Bio from an “overweight” rating to an “equal weight” rating and decreased their target price for the stock from $12.00 to $6.00 in a research report on Thursday, December 19th. William Blair reaffirmed an “outperform” rating on shares of Cabaletta Bio in a research report on Monday, November 18th. Finally, Evercore ISI lowered shares of Cabaletta Bio from an “outperform” rating to an “inline” rating and decreased their price target for the company from $15.00 to $6.00 in a report on Friday, December 20th. One analyst has rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $24.38.

Cabaletta Bio Price Performance

NASDAQ:CABA opened at $2.33 on Friday. The business’s 50-day moving average is $3.16 and its two-hundred day moving average is $4.87. The firm has a market capitalization of $113.88 million, a PE ratio of -1.08 and a beta of 2.37. Cabaletta Bio, Inc. has a 12 month low of $1.76 and a 12 month high of $26.35.

Cabaletta Bio Profile

Cabaletta Bio, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis.